← All candidates
One insider buy in the last year — $585.11 in all.
82 filings on record.
BIIBBIOGEN INC.
NasdaqGS · Healthcare · $29.40B
$217.15
+0.80% · Sep 11
One insider buy in the last year — $585.11 in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 2 sells◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$29.40B
Float
147.2M
100% public
Short % float
Pro
Price / profit
21.4
Price / future profit
12.0
Price / sales
3.0
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Head of Pharm Ops and Tech
Murphy Nicole
Bought $585.11 on Feb 12 — 3 sh @ $195.04, held direct, 0.0% of their stake.
No completed positions to measure
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
77 more transactions on Pro →Context
Wall St
$219.27 avg target
+1.0% vs today · 29 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q1 '26$3.57 act+$0.68
Q4 '25$1.99 act+$0.37
Q3 '25$4.81 act+$0.93
Q2 '25$5.47 act+$1.59
Coverage
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right NowInsider Monkey · 07-05Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.Motley Fool · 07-04BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech PeersStocktwits · 07-02Is Biogen (BIIB) Priced Near Fair Value After Its 57% Run?Simply Wall St. · 07-02
The file stays open
82 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice